Tacrolimus is under clinical development by TFF Pharmaceuticals and currently in Phase II for Lung Transplant Rejection. According to GlobalData, Phase II drugs for Lung Transplant Rejection have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tacrolimus’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tacrolimus is under development for the treatment of lung transplant rejection. and severe asthma. It is a dry powder inhalation (DPI) administered through Inhalational route. It acts by targeting Calcineurin. The drug candidate is being developed based on the Thin Film Freezing (TFF) technology platform.
TFF Pharmaceuticals overview
TFF Pharmaceuticals is a biopharmaceutical company that develops and commercializes inhalable solutions to treat respiratory diseases. The company is investigating TFF VORI, an inhaled dry powder drug targeting invasive pulmonary aspergillosis (IPA); TFF TAC-LAC, an inhaled dry powder used with an inhaler; and vaccines for influenza, ebola, Marburg and alphaviruses. The company is also evaluating a dry powder formulation of Niclosamide against COVID-19. It utilizes its proprietary thin film freezing (TFF) technology platform to improve the solubility of poorly water-soluble drugs and reduce side effects. TFF Pharmaceuticals is headquartered in Fort Worth, Texas, the US.
For a complete picture of Tacrolimus’s drug-specific PTSR and LoA scores, buy the report here.